title: Two grams of sarcosine in schizophrenia - is it too much? A potential role of glutamate-serotonin interaction.
abstract: Glutamate is the main excitatory neurotransmitter in the central nervous system. Dysfunction of the glutamatergic system plays an important role in the pathogenesis of schizophrenia. Therefore, glutamatergic agents such as N-methyl-D-aspartate receptor co-agonists (ie, glycine, D-cycloserine) and glycine transporter type 1 inhibitors (eg, sarcosine) are studied for their efficacy in ameliorating negative and cognitive symptomatology in patients with schizophrenia. We report the case of a 23-year-old schizophrenic patient treated with quetiapine and citalopram, who was offered concomitant sarcosine treatment. After obtaining an informed consent, we started administration of 2 g of sarcosine per day to treat persistent negative and cognitive symptoms. The patient's activity and mood improved within 2 weeks, but in the following 2 weeks the patient reported increased drive, activity, libido, unpleasant inner tension, and irritability. We ruled out hypomania and decided to decrease the daily dose of sarcosine to 1 g, which resulted in reduction of drive and irritability. Activity and mood improved compared with his state before adding sarcosine. We suggest a sarcosine dose between 1 g and 2 g per day with an initial dose of 2 g, but if side effects occur, the dose should be decreased to 1 g per day. We would like to emphasize the clinically important glutamate-serotonin interaction during concomitant use of sarcosine, citalopram, and quetiapine in our patient, which may lead to serious discomfort.
authors: Department of Affective and Psychotic Disorders, Central Clinical Hospital, Medical University of ŁódŸ, ŁódŸ, Poland.
authors: Dominik
authors: D
authors: Strzelecki
authors: Department of Affective and Psychotic Disorders, Central Clinical Hospital, Medical University of ŁódŸ, ŁódŸ, Poland.
authors: Justyna
authors: J
authors: Szyburska
authors: Department of Affective and Psychotic Disorders, Central Clinical Hospital, Medical University of ŁódŸ, ŁódŸ, Poland.
authors: Jolanta
authors: J
authors: Rabe-Jabłońska
keywords: NMDA receptor; dose finding; glutamatergic system; sarcosine; schizophrenia; serotoninergic system